Skip to content
Triangle logo TriangleGet started
← All settings

DISEASE & TREATMENT SETTING

metastatic Pancreatic Neuroendocrine Tumors (Islet Cell Tumors)

Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.

Exact scope

Systemic Therapy for Advanced and Metastatic Disease

Broader topic: Pancreatic Neuroendocrine Tumors (Islet Cell Tumors)

Source population
Not part of this definition
Disease extent
metastatic
Treatment line
Not part of this definition
Stage
Not part of this definition
Resectability
Not part of this definition
Biomarkers, prior therapy and derivation
molecular
    prior therapy
      derivation status
      source-attested
      derivation note
      Scoped from an NCI treatment-summary heading. NCI PDQ is an evidence summary, not a practice guideline, and only the dimensions the heading states are part of this definition.
      source wording
      Systemic Therapy for Advanced and Metastatic Disease

      Study evidence for this setting

      2 linked studies · Applicability is a draft source assessment, not a determination of your eligibility.

      NCT01010126 · Registry condition search · Scope: unclear

      Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer

      6 outcome links · 6 safety-group records · 0 quality-of-life measures

      →

      NCT03375320 · Source cited / selected · Scope: unclear

      Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

      4 outcome links · 4 safety-group records · 2 quality-of-life measures

      →
      Source relationships and population-mapping limitations
      bindings
        mappings

          Download this complete draft source relationship record →

          Preserved source evidence · Not medical advice